Shares of Resverlogix Corp. (TSE:RVX – Get Free Report) reached a new 52-week low on Wednesday . The stock traded as low as C$0.04 and last traded at C$0.04, with a volume of 27000 shares. The stock had previously closed at C$0.05.
Resverlogix Trading Up 12.5 %
The business has a 50 day simple moving average of C$0.05 and a 200-day simple moving average of C$0.06. The stock has a market capitalization of C$8.91 million, a price-to-earnings ratio of -2.23 and a beta of 0.71. The company has a debt-to-equity ratio of -10.95, a current ratio of 0.13 and a quick ratio of 0.04.
About Resverlogix
Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.
Featured Articles
- Five stocks we like better than Resverlogix
- What Are Earnings Reports?
- Is Myers Industries Poised for a Breakout?
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Is BigBear.ai’s 25% Plunge a False Alarm or Fire Sale?
- Industrial Products Stocks Investing
- Broadcom Confirmed Its AI Outlook: Stock to Hit New Highs Soon
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
